Eka Ventures is an early-stage venture fund integrating impact investing into mainstream venture capital by backing sustainable and health-focused consumer businesses.
The London-based bladder care startup secured backing from Eka VC and Joyance to drive its upcoming launch in the United States.
"Since launch, we’ve improved the lives of tens of thousands of people suffering from bladder issues with treatments and education tools. This investment will be critical in us achieving this mission, and expanding our services to the US, where 75m people struggle with these issues. I’m incredibly happy to welcome Eka Ventures and Joyance – who are aligned on our healthcare mission – and to continue our partnership with Samos VC."
The Series A round was led by Planet A Ventures with participation from Maersk Growth, Pale blue dot and Eka Ventures.
"Our mission at HIVED is to decarbonise the logistics industry while setting a new standard for delivery quality. In an industry that has historically failed customers and the planet, we see the incredible need for HIVED’s solution and are rising to that opportunity, building a parcel delivery service that consumers genuinely enjoy and merchants can trust"
The funding round was led by Eka Ventures and will support international studies and product development.
"Existing data suggests that current approaches fall short at accurately detecting and localizing the deadliest cancers that desperately need to benefit from a blood test. At OXcan, we are using state-of-art and unbiased high-throughput proteomics approaches to examine hundreds and thousands of proteins in blood samples from largest studies of their kind for the first time. Combined with proprietary and tailored machine learning approaches, the results are products that fully integrate with existing care pathways and can detect and localize the deadliest cancers with unprecedented sensitivity and specificity."
